

BC Cancer ST Program Updates for September, 2022

AFFECTED APPLICATION(S)	PowerChart: Oncology/Hematology Regimens and PowerPlans
AFFECTED AREA(S)	BC Cancer VC/St. Paul's Hospital (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- **For PowerPlans that are versioned:** If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop up window will appear to indicate a new version is required.
 - Click **Yes** to accept the new version.
 - **Do not** use the Copy Forward functionality to ensure that the updates apply.



- **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below:

PowerPlan: MYDARCBDF and UMYDARBD

Cycles/PowerPlans: MYDARCBDF Cycles 1 to 9 and UMYDARBD Cycles 1 to 8

Changes:
 In the Chemotherapy phase, added a new sentence to the **Bortezomib** order for 1.5mg/m2 dosing option.

ONCP MY MYDARCBDF Cycle 2 - Cycle 2, Chemotherapy (Day 1, 8, 15, 22) (Future Pending) *Est. 12-Aug-2022 08:00 PDT - 28 Days

	Day 1	Day 8	Day 15	Day 22
Component	Future Pending *Est. 12-Aug-2022 08:...	Future Pending *Est. 19-Aug-2022 08:...	Future Pending *Est. 26-Aug-2022 08:...	Future Pending *Est. 02-Sep-2022 08:...
	Actions	Actions	Actions	Actions
Treatment Regimen				
If patient is VZV seropositive and/or at physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg daily while on bortezomib and/or daratumumab and for 4 weeks after discontinuation				
<input checked="" type="checkbox"/> Zero Time	0 hr	0 hr	0 hr	0 hr
<input checked="" type="checkbox"/> bortezomib (bortezomib - oncology)	Planned -60 min	Planned -60 min	Planned -60 min	Planned -60 min
▼ Select an order sentence	Planned	Planned	Planned	Planned
<input checked="" type="checkbox"/> 1.5 mg/m2, SubCutaneous, once oncology, drug form: syringe-inj				
<input type="checkbox"/> 1.3 mg/m2, SubCutaneous, once oncology, drug form: syringe-inj	min	0 min	0 min	0 min
<input type="checkbox"/> 1 mg/m2, SubCutaneous, once oncology, drug form: syringe-inj				
<input type="checkbox"/> 0.7 mg/m2, SubCutaneous, once oncology, drug form: syringe-inj		Planned	Planned	Planned

Versioning: Yes

Jira: CST-178708

PowerPlan: MYDARCBDF, MYDARLDF

Cycles/PowerPlans: All Associated PowerPlans and Regimens

Changes:
 CAP designation of these protocols will be removed on September 1, 2022

New Names in Cerner
 UMYDARCBDF → MYDARCBDF
 UMYDARLDF → MYDARLDF

ONC MY MYDARCBDF First Dose IV (Pending)

▼ Hide additional details

Regimen description: Treatment of Previously Untreated Multiple Myeloma and Not Eligil

+ Add Document Response View Responses

- ONCP MY MYDARCBDF Pretreatment Plan
 - Start
 - ONCP MY MYDARCBDF First Dose IV Cycle 1 - Cycle 1
 - ONCP MY MYDARCBDF Cycle 2 - Cycle 2
 - ONCP MY MYDARCBDF Cycles 3 to 6 - Cycle 3
 - ONCP MY MYDARCBDF Cycles 3 to 6 - Cycle 4
 - ONCP MY MYDARCBDF Cycles 3 to 6 - Cycle 5
 - ONCP MY MYDARCBDF Cycles 3 to 6 - Cycle 6
 - ONCP MY MYDARCBDF Cycles 7 to 9 - Cycle 7
 - ONCP MY MYDARCBDF Cycles 7 to 9 - Cycle 8
 - ONCP MY MYDARCBDF Cycles 7 to 9 - Cycle 9
 - ONCP MY MYDARCBDF Cycles 10+ - Cycle 10

Versioning: Yes

Jira: CST-178712

PowerPlan: GUAVPG

Cycles/PowerPlans: All associated treatment plans

Changes:

In the Lab phase, removed the mandatory LDH lab order on Day 22.

ONCP GU GUAVPG CARBOplatin Option - Cycle 1, Labs (Day 8, 22) (Future Pending) *Est. 18-Aug-2022 08:00 PDT - 21 Days

	Component	Day 8	Day 22
		Future Pending	Future Pending
		*Est. 18-Aug-2022 08:...	*Est. 01-Sep-2022 08:...
		Actions ▼	Actions ▼
<input checked="" type="checkbox"/>	CBC and Differential Blood, once, Order for future visit	Planned	Planned
<input checked="" type="checkbox"/>	Creatinine Level Blood, once, Order for future visit	Planned	Planned
<input checked="" type="checkbox"/>	Alanine Aminotransferase Blood, once, Order for future visit		Planned
<input checked="" type="checkbox"/>	Alkaline Phosphatase Blood, once, Order for future visit		Planned
<input checked="" type="checkbox"/>	Bilirubin Total Blood, once, Order for future visit		Planned

Versioning: Yes

Jira: CST-179871

PowerPlan: GUAVIPNI

Cycles/PowerPlans: GUAVIPNI Induction Plan

Changes:

In the Chemotherapy phase, for **Ipilimumab**:

- Updated the administer over time from 90 minutes to 30 minutes
- Deleted a portion of the order comment 'If no infusion reactions after 2 treatments, may infuse subsequent doses over 30 minutes.'

ONCP GU GUAVIPNI Induction - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 12-Aug

Component
<input checked="" type="checkbox"/> Treatment Regimen
<input checked="" type="checkbox"/> Zero Time
<input checked="" type="checkbox"/> nivolumab (nivolumab - oncology) 3 mg/kg, IV, once oncology, administer over: 30 minute, drug form: bag Use a 0.2 micron in-line filter. Day 1
<input checked="" type="checkbox"/> ipilimumab (ipilimumab - oncology) 1 mg/kg, IV, once oncology, administer over: 30 minute, drug form: bag Use a 0.2 micron in-line filter. Day 1

In the Scheduling phase, updated the **Infusion Chemotherapy Visit** order:

- Special instructions changed to - **Cycle 1**: Chair time 145 minutes; Nurse time 60 minutes
- For **Cycle 2** and onwards - Chair Time: 125 minutes and Nurse Time: 40 minutes

ONCP GU GUAVIPNI Induction - Cycle 1, Scheduling (Initiated Pending)
<input checked="" type="checkbox"/> Infusion Chemotherapy Visit
<input checked="" type="checkbox"/> Follow Up - Clinic - Oncology On Treatment
<input checked="" type="checkbox"/> Follow Up - Clinic - Nurse Telephone Line Care
<input checked="" type="checkbox"/> Go to Chemo Calendar to send next cycle to scheduling wait list

Details for **Infusion Chemotherapy Visit**

Details | Order Comments | Offset Details

Requested Start Date/Time: 12-Aug-2022 0827 PDT

Day of Treatment: Day 1

Ordered Treatment: ONCP GU GUAVIPNI Inductio...

*Scheduling Priority: Within 2 Weeks

*Chair Time: 125 minutes

*Nurse Time: 40 minutes

Reason For Exam: ONCP GU GUAVIPNI Induction

Alternate Scheduling Location:

Special Instructions: Cycle 1: Chair time 145 minutes; Nurse time 60 minutes

Research Study: Yes No

Versioning: Yes

Jira: CST-179875

PowerPlan: BRAVPTRAD, BRAVPTRAT

Cycles/PowerPlans: All associated PowerPlans and Regimens

Changes:

In Chemotherapy phase, removed portion of the order comment from **Trastuzumab** orders: 'Do not substitute HERCEPTIN with trastuzumab biosimilar'.

ONCP BR BRAVPTRAD Cycle 1 - Cycle 1, Chemotherapy (Day 1 to 2) (Future Pending) *Est. 12-Aug-2022 08

Component	Future
<input checked="" type="checkbox"/> trastuzumab (trastuzumab - oncology) 8 mg/kg IV, once oncology, administer over 90 minute, drug form: bag Observe for 60 minutes post-infusion. Day 2	*Est. 12-

For BRAVPTRAT, update the protocol description for all Regimens and PowerPlans to:

Palliative Therapy for Metastatic Breast Cancer using **Pertuzumab**, **Trastuzumab**, and **Paclitaxel** as First-Line Treatment for Advanced Breast Cancer

ONCP BR BRAVPTRAT Cycle 1 - Cycle 1, Chemotherapy (Day 1 to 2) (Future Pending) *Est. 12-Aug-

Component	Future
Link to Protocol: Palliative Therapy for Metastatic Breast Cancer using PERTuzumab, Trastuzumab, and PACLitaxel as First-Line Treatment for Advanced Breast Cancer	

For BRAVPTRAD, update the protocol description for all Regimens and PowerPlans to:

Palliative Therapy for Metastatic Breast Cancer using **Pertuzumab**, **Trastuzumab**, and **Docetaxel** as First-Line Treatment for Advanced Breast Cancer.

ONCP BR BRAVPTRAD Cycle 1 - Cycle 1, Chemotherapy (Day 1 to 2) (Future Pending) *Est. 12-Aug-

Component	Future
Link to Protocol: Palliative Therapy for Metastatic Breast Cancer using PERTuzumab, Trastuzumab, and DOCetaxel as First-Line Treatment for Advanced Breast Cancer	

Versioning: Yes

Jira: CST-179866

PowerPlan: UMYDARBD, UMYDARLD, UMYDARLDF, UMYDARCBDF

Cycles/PowerPlans: All associated PowerPlans and Regimens

Changes:

The existing regimens and Cycle 1 PowerPlans were updated to include "First Dose IV" in the name:

ONC MY UMYDARBD First Dose IV (Pending)

[▶ Show additional details](#)

+ Add Document Response View Responses

A BC Cancer "Compassionate Access Program" (CAP) request form must be c

→ ONCP MY UMYDARBD Pretreatment Plan

Start

ONCP MY UMYDARBD First Dose IV Cycle 1 - Cycle 1

ONCP MY UMYDARBD Cycle 2 - Cycle 2

New Regimens and Cycle 1 PowerPlans were created to be subcutaneous specific for the following protocols:

- UMYDARBD First Dose Subcutaneous
- UMYDARLD Female of Childbearing Potential (FCBP) First Dose Subcutaneous
- UMYDARLD Non Childbearing Potential (NCBP) First Dose Subcutaneous
- UMYDARLDF Female of Childbearing Potential (FCBP) First Dose Subcutaneous
- UMYDARLDF Non Childbearing Potential (NCBP) First Dose Subcutaneous
- UMYDARCBDF First Dose Subcutaneous

ONC MY UMYDARBD First Dose Subcutaneous (Pending)

[▶ Show additional details](#)

+ Add Document Response View Responses

A BC Cancer "Compassionate Access Program" (CAP) request form must be completed and app

→ ONCP MY UMYDARBD Pretreatment Plan

Start

ONCP MY UMYDARBD First Dose Subcutaneous Cycle 1 - Cycle 1

ONCP MY UMYDARBD Cycle 2 - Cycle 2

ONCP MY UMYDARBD Cycles 3 and 4 - Cycle 3

ONCP MY UMYDARBD Cycles 3 and 4 - Cycle 4

ONCP MY UMYDARBD Cycles 5 to 8 - Cycle 5

ONCP MY UMYDARBD Cycles 5 to 8 - Cycle 6

ONCP MY UMYDARBD Cycles 5 to 8 - Cycle 7

ONCP MY UMYDARBD Cycles 5 to 8 - Cycle 8

ONCP MY UMYDARBD Cycles 9+

In the new subcutaneous PowerPlans:

- The repeated acetaminophen/diphenhydramine not required.

ONCP MY UMYDARBD First Dose Subcutaneous Cycle 1 - Cycle 1, Chemother		F
		Component
		*Est.
<input checked="" type="checkbox"/>		acetaminophen 650 mg, PO, once oncology, drug form: tab, Use Patient Sup... 30 to 60 minutes prior to daratumumab. Days 1, 8, 15, 22
<input type="checkbox"/>		loratadine 10 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 to 60 minutes prior to daratumumab. Days 1, 8, 15, 22
<input type="checkbox"/>		diphenhydrAMINE 50 mg, PO, once oncology, drug form: cap, Use Patient Sup... 30 to 60 minutes prior to daratumumab. Days 1, 8, 15, 22
<input type="checkbox"/>		diphenhydrAMINE 50 mg, IV, once oncology, administer over: 15 minute, drug ... 30 to 60 minutes prior to daratumumab. Days 1, 8, 15, 22
<input checked="" type="checkbox"/>		montelukast 10 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 to 60 minutes prior to daratumumab. Day 1
<input type="checkbox"/>		montelukast 10 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 to 60 minutes prior to daratumumab. Days 8, 15, 22
		As needed:
<input checked="" type="checkbox"/>		acetaminophen 650 mg, PO, q4h oncology, PRN other (see comment), drug ... As needed. Days 1, 8, 15, 22
<input checked="" type="checkbox"/>		diphenhydrAMINE 50 mg, IV, q4h oncology, PRN other (see comment), drug fo... For daratumumab reaction. Days 1, 8, 15, 22

- A blue note was added about peripheral IV for Cycle 1 SC plans.

Insert a peripheral IV and saline lock for Cycle 1 Day 1 only for use in the event of a hypersensitivity reaction

- A blue note was added about switching subcutaneous injection sites.

During treatment with subcutaneous daratumumab, administer other subcutaneous drugs at alternative injection sites whenever possible

In the Chemotherapy phase, loratadine has now been listed above diphenhydramine to indicate first preference.

ONCP MY UMYDARBD Cycle 2 - Cycle 2, Chemotherapy (Day 1, 8, 15, 22) (Future	
Component	*Est.
Patient to take own supply of pre-medications. RN/Pharmacist to confirm	
<input checked="" type="checkbox"/> acetaminophen 650 mg, PO, once oncology, drug form: tab, Use Patient Sup... 30 to 60 minutes prior to daratumumab. Days 1, 8, 15, 22	
<input type="checkbox"/> loratadine 10 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 to 60 minutes prior to daratumumab. Days 1, 8, 15, 22	
<input type="checkbox"/> diphenhydrAMINE 50 mg, PO, once oncology, drug form: cap, Use Patient Sup... 30 to 60 minutes prior to daratumumab. Days 1, 8, 15, 22	

For Cycles 2+ PowerPlans where subcutaneous, slow infusion, and rapid infusion options are available, the corresponding scheduling orders are set as such for nurse and chair times to mimic riTUXimab design:

- Nurse Time: 5 minutes
- Chair Time: 5 minutes
- Special Instructions field to include nurse and chair times to guide schedulers

ONCP MY UMYDARBD Cycle 2 - Cycle 2, Scheduling (Initiated Pending)	
<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	22-Sep-2022, Day 1, ONCP MY UMYDARBD Cycle 2 - Cycle 2, Within 2 Weeks, Subcutaneous- Chair: 5 Day 1
<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, Subcutaneous- Chair: 55 min, Nurse: 55 min. IV- Chair: 150 min, Nurse: 70 min, Chair Time Day 8
<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, Subcutaneous- Chair: 55 min, Nurse: 55 min. IV- Chair: 150 min, Nurse: 70 min, Chair Time Day 15
<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, Subcutaneous- Chair: 55 min, Nurse: 55 min. IV- Chair: 150 min, Nurse: 70 min, Chair Time Day 22

Details for Infusion Chemotherapy Visit

Details Order Comments Offset Details

+

Requested Start Date/Time: 22-Sep-2022 1455 PDT Day of Treatment: Day 1

Ordered Treatment: ONCP MY UMYDARBD Cycle ... Alternate Scheduling Location:

*Scheduling Priority: Within 2 Weeks Special Instructions: Subcutaneous- Chair: 55 min, Nurse: 55 min. IV- Chair: 170 min, Nurse: 75 min

*Chair Time: 5 minutes Order Location: BCC VA Chemo

*Nurse Time: 5 minutes Research Study: Yes No

Reason For Exam: ONCP MY UMYDARBD Cycle 2

Versioning: Yes

Jira: CST-178698

Jira Ticket #	CST-179875, CST-179871, CST-179866, CST-178712, CST-178708, CST-178698
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Phone Support: 1-844-214-7444